This post was last updated in April 2026.
WASHINGTON — The Food and Drug Administration always looks a little different after an administration change. Political appointees are swapped out, maybe some offices are restructured.
But the FDA under the Trump administration is starting to look dramatically different. It’s hard to keep track of how many people have left, with departures stemming from early retirements, layoffs, buyout offers, and forced resignations.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in

